FDA Clears Otsuka & Click Therapeutics’ Rejoyn Digital Therapeutic For Depression

Otsuka Pharmaceutical and Click Therapeutics said the FDA cleared Rejoyn, a prescription digital therapeutic authorized for the treatment of major depressive disorder (MDD) symptoms. The clearance is for treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adults with MDD - age 22 years and older - who are on antidepressant medication.  

Rejoyn, a six-week treatment program, is intended to reduce MDD symptoms. It aims to enhance cognitive control of emotion through a combination of clinically validated cognitive emotional training exercises for the brain and brief therapeutic lessons.